JPRN-jRCT2080221925未知1 期
A Phase I study of TSU-68 in combination with S-1 in patients with advanced hepatocellular carcinoma who are not candidates for conventional therapy
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •- ECOG performance status 0-1
- •- Patients who did not respond to surgery, RFA, TAE
排除标准
- •- Large amount of pleural effusion or ascites
- •- Esophageal varices
- •- Simultaneously active double cancer
研究者
相似试验
未知
2 期
An early phase II study of TSU-68 in combination with docetaxel in patients with advanced and metastatic breast cancer progressing anthracycline containing regimen.Breast cancerJPRN-jRCT2080221143Taiho Pharmaceutical Co., Ltd.19
未知
1 期
A Phase I study of TSU-68 in patient with non-small cell lung cancerJPRN-jRCT2080221286Taiho Pharmaceutical Co., Ltd.36
未知
2 期
A randomized phase II trial of TSU-68 in patients with advanced gastric cancerGastric cancerJPRN-jRCT2080221290Taiho Pharmaceutical Co., Ltd.92
未知
1 期
A Phase I Study of TS-1 in Combination with ABI-007 every three weeks in Patients with Unresectable or Recurrent Gastric CancerJPRN-jRCT2080221526Taiho Pharmaceutical Co., Ltd.30
未知
1 期
A Phase I/II Study of S-1 in Combination with Sorafenib in Patients with Metastatic Renal Cell Cancer.Renal cell cancerJPRN-jRCT2080220941Taiho Pharmaceutical Co., Ltd.48
